Haleon trims organic revenue growth outlook amid NA weakness; stock slips

Published 31/07/2025, 11:06

Investing.com -- Haleon (LON:HLN) (NYSE:HLN) shares slipped on Thursday after the company lowered its full-year organic revenue growth forecast, flagging weaker performance in North America that weighed on first-half results.

The stock was down 1.4% in London trading as of 10:04 GMT. 

The maker of Sensodyne and Panadol now expects organic revenue growth of around 3.5% for 2025, down from its previous 4% to 6% range. That range will instead apply to guidance starting in 2026, alongside a new target for high-single-digit adjusted operating profit growth at constant currency.

For 2025, Haleon is also targeting high-single-digit organic operating profit growth.

Total (EPA:TTEF) revenue for the six months ended June declined 3.8% to £5.48 billion, primarily due to soft demand in North America, where the company cited a challenging consumer environment and retailer destocking. In contrast, sales rose in EMEA and Asia-Pacific.

On an organic basis, first-half revenue rose 3.2% year-over-year, slightly below the 3.4% growth expected by analysts.

"This is a weak update," Jefferies analysts said in a note. "The organic sales growth guide cut is more extreme than feared."

Adjusted operating profit for the first six months rose 9.9% to £1.24 billion, narrowly beating expectations.

Adjusted pretax profit came in at £1.11 billion.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.